These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20112801)

  • 1. [A case of cystic maculopathy during paclitaxel therapy].
    Ito S; Okuda M
    Nippon Ganka Gakkai Zasshi; 2010 Jan; 114(1):23-7. PubMed ID: 20112801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-leaking Cystoid Maculopathy Secondary to Systemic Paclitaxel.
    Modi D; Dubovy SR
    Ophthalmic Surg Lasers Imaging Retina; 2013; 44(2):183-6. PubMed ID: 23429715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystic maculopathy with normal capillary permeability secondary to docetaxel.
    Teitelbaum BA; Tresley DJ
    Optom Vis Sci; 2003 Apr; 80(4):277-9. PubMed ID: 12692483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel maculopathy.
    Joshi MM; Garretson BR
    Arch Ophthalmol; 2007 May; 125(5):709-10. PubMed ID: 17502517
    [No Abstract]   [Full Text] [Related]  

  • 5. [A Case of a Corneal Disorder after Breast Cancer Treatment with Nab-paclitaxel].
    Hosotani Y; Morimatsu T; Takata M; Mimura O
    Nippon Ganka Gakkai Zasshi; 2016 Jun; 120(6):449-53. PubMed ID: 27487717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cystoid macular edema secondary to nanoparticle albumin-bound Paclitaxel therapy.
    Rahimy E; Sarraf D
    Ophthalmic Surg Lasers Imaging Retina; 2013; 44(2):187-9. PubMed ID: 23421925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiographically silent cystoid macular oedema secondary to paclitaxel therapy.
    Georgakopoulos CD; Makri OE; Vasilakis P; Exarchou A
    Clin Exp Optom; 2012 Mar; 95(2):233-6. PubMed ID: 22023333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of paclitaxel-induced maculopathy treated with methazolamide.
    Koo NK; Kim YC
    Korean J Ophthalmol; 2012 Oct; 26(5):394-7. PubMed ID: 23060729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nab-paclitaxel-induced cystoid macular edema in a patient with pre-existing optic neuropathy.
    Park E; Goldberg NR; Adams S
    Anticancer Drugs; 2016 Jul; 27(6):580-4. PubMed ID: 26982237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
    Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of paclitaxel-induced maculopathy with oral acetazolamide.
    Meyer KM; Klink T; Ugurel S; Bröcker EB
    Graefes Arch Clin Exp Ophthalmol; 2012 Mar; 250(3):463-4. PubMed ID: 21431400
    [No Abstract]   [Full Text] [Related]  

  • 12. [Weekly paclitaxel therapy for metastatic breast cancer].
    Kokufu I; Taniguchi H; Kimura F; Fukuda K; Yamamoto M; Yano T; Yamada K
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):221-6. PubMed ID: 11865627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock].
    Ikeda M; Sonoo H; Oota Y; Fujii S; Shimo T; Miyake A; Seki M; Nomura T; Yamamoto Y; Shiiki S; Nakashima K; Tanaka K; Kurebayashi J
    Gan To Kagaku Ryoho; 2010 Dec; 37(13):2917-20. PubMed ID: 21160270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer.
    Christodoulou C; Klouvas G; Pateli A; Mellou S; Sgouros J; Skarlos DV
    Anticancer Res; 2003; 23(1B):737-44. PubMed ID: 12680177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystoid macular edema secondary to nab-paclitaxel therapy.
    Murphy CG; Walsh JB; Hudis CA; Lake D; Theodoulou M
    J Clin Oncol; 2010 Nov; 28(33):e684-7. PubMed ID: 20805460
    [No Abstract]   [Full Text] [Related]  

  • 16. Anisocoria as a side effect of paclitaxel treatment.
    Halámková J; Adámková Krákorová D; Demlová R
    Klin Onkol; 2021; 34(4):306-308. PubMed ID: 34905931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possibility of Müller Cell Dysfunction as the Pathogenesis of Paclitaxel Maculopathy.
    Nakao S; Ikeda Y; Emi Y; Ishibashi T
    Ophthalmic Surg Lasers Imaging Retina; 2016 Jan; 47(1):81-4. PubMed ID: 26731216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody.
    Adachi A; Horikawa T
    J Dermatol; 2007 Jul; 34(7):473-6. PubMed ID: 17584326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.